Skip to main content
رجوع
Watch Compare

Metagenomi Therapeutics, Inc.

جودة البيانات: 100%
MGX
Nasdaq Manufacturing Chemicals
KWD 1.38
▼ KWD 0.02 (-1.08%)
القيمة السوقية: 51.73 M
السعر
KWD 1.38
القيمة السوقية
51.73 M
نطاق اليوم
KWD 1.35 — KWD 1.41
نطاق 52 أسبوعًا
KWD 1.25 — KWD 3.95
حجم التداول
106,073
فتح KWD 1.36
متوسط 50 يوم / 200 يوم
KWD 1.50
8.06% below
متوسط 50 يوم / 200 يوم
KWD 1.90
27.47% below

Quick Summary

النقاط الرئيسية

Negative free cash flow of -89.47 M
Capital efficient — spends only 2.28% of revenue on capex

النمو

Revenue Growth (5Y)
N/A
Revenue (1Y)-51.79%
Earnings (1Y)N/A
FCF Growth (3Y)N/A

الجودة

Return on Equity
-46.95%
أعلى من متوسط القطاع (-53.47%)
ROIC-33.17%
Net Margin-348.54%
Op. Margin-380.85%

الأمان

Debt / Equity
N/A
Current Ratio6.42
Interest CoverageN/A

التقييم

PE (TTM)
-0.59
أعلى من متوسط القطاع (-1.47)
P/B Ratio0.29
EV/EBITDAN/A
Dividend YieldN/A

تاريخ السعر

الاتجاهات المالية

مقارنة الأقران

مقابل وسيط قطاع Manufacturing (1364 نظير)
المقياس السهم وسيط القطاع
P/E -0.6 -1.5
P/B 0.3 1.6
ROE % -47.0 -53.5
Net Margin % -348.5 -41.5
Rev Growth 5Y % — 1.8
D/E — 0.3

ETFs Holding This Stock

BRUSX BRUSX
0.59% weight
BRSIX BRSIX
0.13% weight
AVDS logo AVDS Avantis International Small Cap Equity ETF
0.00% weight

All Fundamental Metrics
Growth
Revenue Growth (1Y) -51.79% Revenue Growth (3Y) N/A
Earnings Growth (1Y) N/A Earnings Growth (3Y) N/A
Revenue Growth (5Y) N/A Earnings Growth (5Y) N/A
Profitability
Revenue (TTM) 25.21 M Net Income (TTM) -87.87 M
ROE -46.95% ROA -33.78%
Gross Margin N/A Operating Margin -380.85%
Net Margin -348.54% Free Cash Flow (TTM) -89.47 M
ROIC -33.17% FCF Growth (3Y) N/A
Safety
Debt / Equity N/A Current Ratio 6.42
Interest Coverage N/A Asset Turnover 0.10
Working Capital 160.24 M Tangible Book Value 178.45 M
Dividends
Dividend Yield N/A Payout Ratio N/A
Dividend Growth (3Y) N/A Dividend Growth (5Y) N/A
Consecutive Div Years N/A
Valuation
P/E Ratio -0.59 Forward P/E N/A
P/B Ratio 0.29 P/S Ratio 2.05
PEG Ratio N/A Forward PEG N/A
EV/EBITDA N/A Fwd EV/EBITDA N/A
Forward P/S N/A Fwd Earnings Yield N/A
FCF Yield -172.95%
Market Cap 51.73 M Enterprise Value 18.96 M
Per Share
EPS (Diluted TTM) -2.36 Revenue / Share 0.67
FCF / Share -2.38 OCF / Share -2.36
EPS CAGR (1Y) N/A EPS CAGR (5Y) N/A
EPS CAGR (10Y) N/A
Efficiency
CapEx / Revenue 2.28% FCF Conversion 101.82%
SBC-Adj. FCF -103.68 M Growth Momentum N/A

Income Statement

Annual, most recent first
Metric FY2025 FY2024
Revenue 25.21 M 52.30 M
Net Income -87.87 M -78.06 M
EPS (Diluted) -2.36 -2.36
Gross Profit — —
Operating Income -96.01 M -88.90 M
EBITDA — —
R&D Expenses 94.43 M 109.18 M
SG&A Expenses — —
D&A — —
Interest Expense — —
Income Tax -58,000.0 -5.51 M

Balance Sheet

Annual, most recent first
Metric FY2025 FY2024
Total Assets 221.10 M 324.60 M
Total Liabilities 62.51 M 89.74 M
Shareholders' Equity 158.60 M 234.86 M
Total Debt — —
Cash & Equivalents 41.72 M 27.39 M
Current Assets 165.54 M 257.96 M
Current Liabilities 22.93 M 37.31 M